Amendments to the Claims

Claims 1-20. (Cancelled)

- 21. (Currently Amended) A compound selected from the group consisting of:
- $\hbox{$4\hbox{-}[5$-(Phenethylamino-methyl)$-thiophen-2-yloxy]$-benzamide}$

4-{5-[(3-Methyl-butylamino)-methyl]-thiophen-2-yloxy}-benzamide

4-(5-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-thiophen-2-yloxy)-benzamide

 $\hbox{$4-\{5-[(2-Cyclopentyl-ethylamino)-methyl]-thiophen-2-yloxy}$-benzamide$

4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-thiophen-2-yloxy}-benzamide

4-{5-[(3,3-Dimethyl-butylamino)-methyl]-thiophen-2-yloxy}-benzamide

 $3-Methoxy-4-[5-(phenethylamino-methyl)-thiophen-2-yloxy]-benzamide \\ \frac{hydrochloride}{}$

 $3-Methoxy-4-\{5-[(3-methyl-butylamino)-methyl]-thiophen-2-yloxy\}-benzamide \\ \frac{hydrochloride}{hydrochloride}$

4-[5-(2-Phenethylamino-ethyl)-thiophen-2-yloxy]-benzamide-hydrochloride

5-{4-[(3-Ethylpentylamino)methyl]phenoxy}thiophene-2-carboxamide

2-{4-[(3-Methylbutylamino)methyl]phenoxy}thiazole-5-carboxamide

 $2\hbox{-}(4\hbox{-}\{[2\hbox{-}(Tetrahydropyran-4-yl)ethylamino}]\ methyl\} phenoxy) thiazole-5\hbox{-}carboxamide \\ \underline{methanesulfonate}$

and aor a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer or diastereomeric mixture thereof.

- 22. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of <u>formula IClaim 21</u> in association with a carrier, diluent and/or excipient.
 - 23. (Cancelled)
 - 24. (Cancelled)
 - 25. (Cancelled)
 - 26. (Cancelled)
 - 27. (Cancelled)
 - 28. (Cancelled)